Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.43 |
| ▸ | EED | O75530 | 1/20 | 0.41 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.41 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.41 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.41 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29152603 | 1.00 | JAK2 (0.43) | JAK2JAK3PTK2PDE4BEED | |
| SCHEMBL30798625 | 0.91 | PDE4B (0.45) | JAK2JAK3PTK2PDE4BEED | |
| SCHEMBL29152533 | 0.91 | PDE4B (0.45) | JAK2JAK3PTK2PDE4BEED | |
| SCHEMBL24717421 | 0.91 | PDE4B (0.45) | JAK2JAK3PTK2PDE4BEED | |
| SCHEMBL30798370 | 0.91 | PDE4B (0.45) | JAK2JAK3PTK2PDE4BEED | |
| SCHEMBL24717417 | 0.91 | PDE4B (0.45) | JAK2JAK3PTK2PDE4BEED | |
| SCHEMBL30606458 | 0.88 | PDE4B (0.53) | JAK2JAK3PTK2PDE4BEED | |
| SCHEMBL16991907 | 0.88 | PDE4B (0.53) | JAK2JAK3PTK2PDE4BEED | |
| SCHEMBL24244951 | 0.84 | PDE4B (0.46) | JAK2JAK3PTK2PDE4BUSP30 | |
| SCHEMBL22551223 | 0.84 | PDE4B (0.46) | JAK2JAK3PTK2PDE4BUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325547-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| EP-4323352-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325547-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | JAK2 916/4885JAK3 1959/4885PTK2 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.